Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Oncology

• Publication date

  2017-08-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.71.7629PMID 28854067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

  2017cited by this paper
• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

  2016cited by this paper
• Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

  2015cited by this paper
• Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer

  2015cited by this paper
• Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models

  2013cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Comprehensive genomic characterization of squamous cell lung cancers

  2012cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

  2010cited by this paper
• A High Number of CD8+ T Cells Infiltrated in NSCLC Tissues is Associated With a Favorable Prognosis

  2010cited by this paper
• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

  2010cited by this paper
• The role of inflammation in the pathogenesis of non-small cell lung cancer.

  2010cited by this paper
• Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms.

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008cited by this paper
• Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy

  2007cited by this paper
• Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

  2007cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

  2006cited by this paper
• Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.

  2005cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Digestive System Toxicities of Immune Checkpoint Inhibitors: Mechanisms and Clinical Implications

  2026cites this paper
• Lung cancer in women: current evidence and future research priorities.

  2026cites this paper
• Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.

  2025cites this paper
• Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?

  2025cites this paper
• Spatial Omics Profiling of Treatment-Naïve Lung Adenocarcinoma with Brain Metastasis as the Initial Presentation

  2025cites this paper
• The Effects of Race on Anti-PD-(L)1 Monoclonal Antibodies in Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis.

  2025cites this paper
• Recent Advances in the Biosensors for the Detection of Lung Cancer Biomarkers: A Review.

  2025cites this paper
• Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis

  2025cites this paper
• Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis

  2025influential citation
• A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors.

  2025cites this paper
• Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis

  2025cites this paper
• Gastrointestinal Toxicities of Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients. A Review

  2025cites this paper
• Incidence of pneumonitis with CTLA-4 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

  2025cites this paper
• Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis

  2025cites this paper
• The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer

  2025cites this paper
• Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis

  2025cites this paper
• Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC

  2025cites this paper
• Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

  2024cites this paper
• Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy

  2024cites this paper
• Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis.

  2024cites this paper
• Immunotherapy in the Treatment of Cancer: Today and Tomorrow

  2024cites this paper
• The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.

  2024cites this paper
• A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis

  2024cites this paper
• The Effect of Sex on the Therapeutic Efficiency of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials

  2024cites this paper
• Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials.

  2024cites this paper
• The Association Between Modified Albumin-Bilirubin (mALBI) and Survival in Advanced Non-small Cell Lung Cancer Patients Treated With Immunotherapy

  2024cites this paper
• Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis

  2024cites this paper
• Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis

  2024cites this paper
• Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system

  2024cites this paper
• Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression

  2024cites this paper
• Cell cycle dysregulation in cancer.

  2024cites this paper
• Treatment-related adverse events of combination chemoimmunotherapy versus chemotherapy alone in first-line treatment for non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials

  2024cites this paper
• Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: A systematic review and meta-analysis.

  2024cites this paper
• Association between sex and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.

  2024cites this paper
• Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.

  2024cites this paper
• Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

  2024cites this paper
• A comprehensive review of immune checkpoint inhibitors for cancer treatment.

  2024cites this paper
• Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies

  2024cites this paper
• Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer

  2024cites this paper
• Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors

  2024cites this paper
• Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.

  2024cites this paper
• Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer

  2023cites this paper
• Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies.

  2023cites this paper
• Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

  2023cites this paper
• The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis

  2023cites this paper
• Emerging evidence for adapting radiotherapy to immunotherapy

  2023cites this paper
• Immunotherapy through the Lens of Non-Small Cell Lung Cancer

  2023cites this paper
• Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies

  2023cites this paper
• Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis

  2023cites this paper
• Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

  2023cites this paper
• Facial palsy induced by immune checkpoint blockade: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.

  2023cites this paper
• The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysis

  2023cites this paper
• Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China

  2023cites this paper
• Near-Infrared Light-Activatable Melanized Paclitaxel Nano–Self-Assemblies for Synergistic Anti-tumor Therapy

  2023cites this paper
• Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

  2023influential citation
• Fragmented antibodies in non-small cell lung cancer: a novel nano-engineered delivery system for detection and treatment of cancer.

  2023cites this paper
• Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials

  2023cites this paper
• Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials

  2023cites this paper
• Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review

  2023cites this paper
• Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

  2023cites this paper
• Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis

  2023cites this paper
• The characteristics of oncological clinical trials investigating the synergistic effect of radiotherapy and immune checkpoint inhibitors: a cross-sectional study

  2023cites this paper
• Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis

  2023cites this paper
• Chemotherapy-induced nanovaccines implement immunogenicity equivalence for improving cancer chemoimmunotherapy.

  2023cites this paper
• Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors

  2023influential citation
• Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials

  2023cites this paper
• The Role of Immunotherapy or Immuno-Chemotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review

  2023influential citation
• Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade

  2022cites this paper
• Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy

  2022cites this paper
• Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center

  2022cites this paper
• The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression

  2022cites this paper
• Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis

  2022cites this paper
• Neoantigens and their clinical applications in human gastrointestinal cancers

  2022cites this paper
• Thyroid Dysfunction in Non‐Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta‐Analysis

  2022cites this paper
• The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis

  2022cites this paper
• Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis

  2022cites this paper
• Effectiveness of immunological agents in non‐small cell lung cancer

  2022cites this paper
• Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials

  2022cites this paper
• Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment

  2022cites this paper
• Immune checkpoint inhibitor-induced arthralgia is tightly associated with improved overall survival in cancer patients.

  2022cites this paper
• Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives

  2022cites this paper
• Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis

  2022cites this paper
• Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

  2022cites this paper
• The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis

  2022cites this paper
• Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors

  2022cites this paper
• Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights

  2022cites this paper
• The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study.

  2022cites this paper
• Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis

  2022cites this paper
• The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment

  2022cites this paper
• A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC

  2022cites this paper
• First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

  2022cites this paper
• Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis

  2022cites this paper
• Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets

  2022cites this paper
• Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)

  2022cites this paper
• Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events

  2022cites this paper
• Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells

  2022cites this paper
• Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials

  2022cites this paper
• Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis

  2022cites this paper
• The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis

  2022cites this paper
• Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases

  2022cites this paper